Related Experiment Video
Updated: Aug 9, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Randomized trial of carvedilol in treatment of congestive heart failure
Insights
Carvedilol significantly reduced mortality in heart failure patients. This randomized trial found lower death rates in the Carvedilol group compared to placebo, highlighting its therapeutic benefit.
Area of Science:
- Cardiology
- Clinical Trials
- Pharmacology
Background:
- A large multicenter randomized clinical trial was conducted.
- The study focused on patients with clinical heart failure and ejection fraction < 0.35.
Purpose of the Study:
- To evaluate the efficacy of Carvedilol compared to placebo.
- To assess the impact of Carvedilol on mortality in heart failure patients.
Main Methods:
- Data on exposure and death were collected at 50-day intervals up to 400 days.
- Comparative mortality tables were constructed for both groups, considering all ages, sexes, and durations.
- Expected mortality derivation was detailed.
Main Results:
- Excess mortality was substantially higher in the placebo group.
- The mortality ratio and excess death rate were significantly greater in patients not receiving Carvedilol.
Conclusions:
- Carvedilol treatment demonstrated a significant reduction in mortality.
- The findings support the use of Carvedilol in managing heart failure with reduced ejection fraction.
Background:
Members of the U.S. Cardevivol Study Group at Lovelace Scientific Resources, Albuquerque, NM, designed and carried out a large multicenter randomized clinical trial of Cardevilol vs placebo in patients with clinical heart failure and ejection fraction < 0.35.
Results:
Derived exposure and death data at 50-day intervals to 400 days were used to construct tables of comparative mortality, all ages, both sexes and all durations to 400 days combined, in the Carvedilol and the placebo groups Derivation of expected mortality is explained in detail.
Conclusions:
Excess mortality, measured as mortality ratio or excess death rate, was much higher in the placebo than in the Cardevilol-treated group.
More Related Videos
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
08:33A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers
Published on: January 5, 2024
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: β-Blockers
Coronary Artery Disease V: Interprofessional Care
Heart Failure V: Medical Management
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care